Lenalidomid Zentiva (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4 E3 ubiquitin ligase complex, changing its substrate specificity. This triggers the degradation of transcription factors Ikaros and Aiolos, leading to reduced cytokine production, inhibition of new blood‑vessel formation, and direct anti‑tumor effects on malignant plasma and lymphoid cells.

The specific dose of Lenalidomid Zentiva is determined by the prescribing physician based on the patient’s diagnosis, disease stage, renal function, and other clinical factors. Healthcare professionals follow approved dosing guidelines and adjust the regimen as needed for safety and efficacy.

Lenalidomid Zentiva is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because it can cause fetal harm. Women of reproductive potential must use effective contraception. The safety of the drug during breastfeeding has not been established, so breastfeeding is generally not recommended while on therapy.

To request Lenalidomid Zentiva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lenalidomid Zentiva belongs to the class of immunomodulatory drugs, offering a distinct mechanism compared with proteasome inhibitors or monoclonal antibodies. It provides oral administration and can be combined with dexamethasone or other agents, often resulting in improved progression‑free survival for patients who are eligible for this therapy.

Lenalidomid Zentiva should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, excessive heat, and direct sunlight to maintain stability and potency throughout its shelf life.

Lenalidomid Zentiva is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. Patients should swallow the tablet whole and follow any specific instructions regarding timing relative to other medications.

The most serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, severe cutaneous reactions like Stevens‑Johnson syndrome, and the potential for secondary malignancies. Regular monitoring of blood counts, coagulation status, and skin condition is essential to detect these complications early.

Lenalidomid Zentiva should not be used by individuals who are pregnant, have known hypersensitivity to lenalidomide or any excipients, or have uncontrolled infections without appropriate prophylaxis. Patients with severe renal impairment may require dose adjustments, and clinicians should evaluate suitability on a case‑by‑case basis.